Quick Answer
Cullinan Therapeutics, Inc. reported Cash and Equivalents of $88.33 million for fiscal year 2025.
Cullinan Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $88.33M | +6.4% |
| 2024 | $83.00M | -15.7% |
| 2023 | $98.43M | -37.0% |
| 2022 | $156.15M | +161.2% |
| 2021 | $59.77M | -64.5% |
| 2020 | $168.20M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $103.33M | +1.2% | +41.9% |
| June 30, 2025 | $72.82M | -36.7% | -5.0% |
| March 31, 2025 | $76.66M | +3.3% | -7.7% |
| December 31, 2024 | $83.00M | -15.7% | -18.7% |
| September 30, 2024 | $102.08M | +57.4% | -11.2% |
| June 30, 2024 | $115.02M | -18.9% | +55.0% |
| March 31, 2024 | $74.23M | -39.2% | -24.6% |
| December 31, 2023 | $98.43M | -37.0% | +51.8% |
- Cullinan Therapeutics, Inc. showed an increase of +6.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, Cullinan Therapeutics, Inc.’s cash and equivalents has declined by 47.5% (from $168.20 million to $88.33 million).
- The most recent figure is from Cullinan Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: